On July 5 and 6, the International Symposium “Health Regulation in a Post-Covid-19 World” was organized by the Federal Commission for the Protection against Health Risks (COFEPRIS in Spanish) in celebration of its 20th Anniversary. The event was attended by the European Medicines Agency (EMA) and the Pan American Health Organization (PAHO). At the end of the event, the Deputy Director of the Secretariat of Health, Hugo López Gatell, highlighted the signing of the declaration “Towards Equity in Health Regulation in the face of Emerging Diseases” in order to establish mechanisms for international harmonization and convergence to exchange regulatory practices.
At the event, Lopez Gatell called on the region’s health regulatory agencies to adhere to the joint declaration with the aim of exchanging best practices in order to have safe health supplies in the medium term, in addition to mentioning that he will seek to promote the adoption of equivalence agreements between agencies to improve access to medicines. In turn, the agreements reached by the agencies participating in the event will be submitted to the steering committee of the Pan American Health Organization (PAHO) to invite working groups for each regulatory process to promote regulatory improvement.
The event was also attended by representatives of different health regulatory agencies such as the director of the EMA, Emer Cooke, who reported that they have made progress during the pandemic context with the implementation of pharmacovigilance inspections in the Latin American region, with the help of the agencies in the area that have shared information in real time to avoid duplication of work. The entity hopes that this will be a practice that will last over time, in addition to defining as a priority the development of transparency of data on clinical trials and drug innovation in the region.
On the other hand, Jarbas Barbosa Da Silva, deputy director of the Pan American Health Organization (PAHO), stated that the region’s health agencies must establish as a priority the streamlining and simplification of processes and mechanisms for drug licenses, registrations and authorizations.